{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=20", "query": { "intervention": "matched control group", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2815, "total_pages": 282, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T05:10:57.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01674218", "title": "Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tuberculosis" ], "interventions": [ { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "PA-824", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 74, "start_date": "2012-09", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-11-14", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674218" }, { "nct_id": "NCT05933746", "title": "Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress, Emotional", "Sleep Disturbance" ], "interventions": [ { "name": "Sleep Hygiene Intervention", "type": "BEHAVIORAL" }, { "name": "Non-behavioral Sleep Education", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "18 Years to 24 Years" }, "enrollment_count": 108, "start_date": "2022-03-01", "completion_date": "2022-07-15", "has_results": false, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933746" }, { "nct_id": "NCT04836442", "title": "PFI Hazardous Drinkers With Subclinical PTSD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hazardous Drinking", "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Alcohol-PTSD-PFI (AP-PFI)", "type": "OTHER" }, { "name": "Active Comparison Condition (C-PFI)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 100, "start_date": "2022-07", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04836442" }, { "nct_id": "NCT06226883", "title": "A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammatory Bowel Diseases", "Crohn's Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "MORF-057", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 385, "start_date": "2024-07-18", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 25, "location_summary": "Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06226883" }, { "nct_id": "NCT04184882", "title": "A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duchenne Muscular Dystrophy (DMD)" ], "interventions": [ { "name": "Bocidelpar", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "MALE", "summary": "8 Years to 16 Years · Male only" }, "enrollment_count": 8, "start_date": "2021-02-24", "completion_date": "2022-09-04", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 5, "location_summary": "Sacramento, California • Kansas City, Kansas • Baltimore, Maryland + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04184882" }, { "nct_id": "NCT06016842", "title": "A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis (PBC)" ], "interventions": [ { "name": "Elafibranor", "type": "DRUG" }, { "name": "Matched 80 mg placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2023-08-31", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 43, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016842" }, { "nct_id": "NCT00462280", "title": "Lovastatin in Treating Patients At High Risk of Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precancerous Condition", "Stage 0 Melanoma", "Stage I Melanoma", "Stage II Melanoma" ], "interventions": [ { "name": "lovastatin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2007-05", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 3, "location_summary": "Orange, California • Tampa, Florida • Salt Lake City, Utah", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462280" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID-19", "Hypersomnia", "Sleep Disturbance" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Modafinil Placebo", "type": "DRUG" }, { "name": "Solriamfetol", "type": "DRUG" }, { "name": "Solriamfetol Placebo", "type": "DRUG" }, { "name": "Melatonin", "type": "DRUG" }, { "name": "Melantonin Placebo", "type": "DRUG" }, { "name": "Tailored lighting (TL) Active", "type": "DEVICE" }, { "name": "Tailored lighting (TL) Placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2024-07-31", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06404086" }, { "nct_id": "NCT03197870", "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonproliferative Diabetic Retinopathy" ], "interventions": [ { "name": "AKB-9778", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyePoint Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 167, "start_date": "2017-06-09", "completion_date": "2019-02-09", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03197870" }, { "nct_id": "NCT05823142", "title": "Health Behavior Intervention for Adults With Type 1 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type1diabetes" ], "interventions": [ { "name": "CB Sleep", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 300, "start_date": "2023-12-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-11-04T05:10:57.300Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05823142" } ] }